Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021114 | 0.92 | TRPV1 (0.63) | TRPV1PKMDGAT2ROCK2ROCK1 | |
| SCHEMBL4025727 | 0.87 | TRPV1 (0.66) | TRPV1PKMROCK2ROCK1MAPK1 | |
| SCHEMBL4023559 | 0.86 | TRPV1 (0.67) | TRPV1PKMROCK2ROCK1MAPK1 | |
| SCHEMBL6066195 | 0.81 | TRPV1 (0.61) | TRPV1PKMROCK2ROCK1MAPK1 | |
| SCHEMBL6441156 | 0.80 | TRPV1 (0.53) | TRPV1 | |
| SCHEMBL6603939 | 0.76 | TRPV1 (0.59) | TRPV1PKMROCK2ROCK1TSHR | |
| SCHEMBL4022493 | 0.72 | TRPV1 (0.70) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL2727166 | 0.72 | TRPV1 (0.61) | TRPV1 | |
| SCHEMBL4029027 | 0.72 | TRPV1 (0.63) | TRPV1MAPK1CYP3A4CYP2D6 | |
| SCHEMBL4019256 | 0.71 | TRPV1 (0.56) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, TMEM109, VIPR1 | TRPV1 1/4885PKM 4258/4885DGAT2 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.